|
| 36600665 | Hurricane Florence and suicide mortality in North Carolina: a controlled interrupted time-series analysis. | Inj Prev | 2023 |
| 36302890 | Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology. | NPJ Precis Oncol | 2022 |
| 35580297 | AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With <i>EGFR</i> Exon 19 Deletion or L858R Mutations. | J Clin Oncol | 2022 |
| 35701110 | Innovations in suicide prevention research (INSPIRE): a protocol for a population-based case-control study. | Inj Prev | 2022 |
| 32339229 | The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study. | J Natl Cancer Inst | 2021 |
| 33742104 | Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study. | NPJ Precis Oncol | 2021 |
| 33542076 | Optimized EGFR Blockade Strategies in <i>EGFR</i> Addicted Gastroesophageal Adenocarcinomas. | Clin Cancer Res | 2021 |
| 33775530 | Comprehensive genomic profiling of metastatic collecting duct carcinoma, renal medullary carcinoma, and clear cell renal cell carcinoma. | Urol Oncol | 2021 |
| 34376553 | Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. | J Immunother Cancer | 2021 |
| 34476330 | Genomic Profiling of Combined Hepatocellular Cholangiocarcinoma Reveals Genomics Similar to Either Hepatocellular Carcinoma or Cholangiocarcinoma. | JCO Precis Oncol | 2021 |
| 34333275 | Genomic profiling of solid tumors harboring BRD4-NUT and response to immune checkpoint inhibitors. | Transl Oncol | 2021 |
| 33217343 | Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment. | Cancer Cell | 2021 |
| 32918774 | Targetable BRAF and RAF1 Alterations in Advanced Pediatric Cancers. | Oncologist | 2021 |
| 32861617 | Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma. | Eur Urol Focus | 2021 |
| 32682887 | Clinical, histopathologic, and molecular profiles of PRKAR1A-inactivated melanocytic neoplasms. | J Am Acad Dermatol | 2021 |
| 31604903 | The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA. | Oncologist | 2020 |
| 31959546 | Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the Bladder. | Eur Urol | 2020 |
| 31985116 | Urothelial cancer harbours EGFR and HER2 amplifications and exon 20 insertions. | BJU Int | 2020 |
| 32043779 | Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2-Year Durable Response. | Oncologist | 2020 |
| 33125909 | Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol. | Lancet Oncol | 2020 |
| 32966992 | Characterization of Clinical Cases of Malignant PEComa via Comprehensive Genomic Profiling of DNA and RNA. | Oncology | 2020 |
| 32823229 | Retrospective analysis of real-world data to determine clinical outcomes of patients with advanced non-small cell lung cancer following cell-free circulating tumor DNA genomic profiling. | Lung Cancer | 2020 |
| 33015532 | Unique Genomic Landscape of High-Grade Neuroendocrine Cervical Carcinoma: Implications for Rethinking Current Treatment Paradigms. | JCO Precis Oncol | 2020 |
| 32903788 | Pan-Cancer Analysis of <i>BRCA1</i> and <i>BRCA2</i> Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity. | JCO Precis Oncol | 2020 |
| 32949172 | Attrition of Patients on a Precision Oncology Trial: Analysis of the I-PREDICT Experience. | Oncologist | 2020 |
| 32923870 | Identifying Opportunities and Challenges for Patients With Sarcoma as a Result of Comprehensive Genomic Profiling of Sarcoma Specimens. | JCO Precis Oncol | 2020 |
| 32723837 | Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER<sup>+</sup> Metastatic Breast Cancer. | Clin Cancer Res | 2020 |
| 32183953 | Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. | Cancer Cell | 2020 |
| 32399016 | Exceptional Response to Everolimus in a Patient with Metastatic Castrate-Resistant Prostate Cancer Harboring a PTEN Inactivating Mutation. | Case Rep Oncol | 2020 |
| 32368168 | Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the <i>ALK</i> Gene Have Durable Responses to ALK Kinase Inhibitors. | Lung Cancer (Auckl) | 2020 |
| 30025711 | Genomic Characterization of Testicular Germ Cell Tumors Relapsing After Chemotherapy. | Eur Urol Focus | 2020 |
| 30582752 | Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities. | Cancer | 2019 |
| 35100719 | Atypical <i>RAS</i> Mutations in Metastatic Colorectal Cancer. | JCO Precis Oncol | 2019 |
| 30181314 | Genomic Landscape of Adult and Pediatric <i>BCR-ABL1</i>-Like B-Lymphoblastic Leukemia Using Parallel DNA and RNA Sequencing. | Oncologist | 2019 |
| 30038380 | Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia. | Leukemia | 2019 |
| 30108156 | Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden. | Oncologist | 2019 |
| 31588020 | Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. | Cancer Cell | 2019 |
| 31292271 | Pan-Cancer Analysis of <i>CDK12</i> Loss-of-Function Alterations and Their Association with the Focal Tandem-Duplicator Phenotype. | Oncologist | 2019 |
| 31602320 | Genomic profiling of cell-free circulating tumor DNA in patients with colorectal cancer and its fidelity to the genomics of the tumor biopsy. | J Gastrointest Oncol | 2019 |
| 31427573 | Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients. | Nat Commun | 2019 |
| 31399473 | The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy. | Clin Cancer Res | 2019 |
| 31483290 | Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma. | J Clin Invest | 2019 |
| 31447233 | Erratum to "Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/G and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib" [Lung Cancer, 108 (June 2017) 228-231]. | Lung Cancer | 2019 |
| 31445211 | A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability and Pan-Tumor Characterization of 1000 Microsatellite Instability-High Cases in 67,000 Patient Samples. | J Mol Diagn | 2019 |
| 31249137 | <i>FGFR2</i>-Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape. | Oncologist | 2019 |
| 31218271 | Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors. | JCO Precis Oncol | 2019 |
| 30836094 | Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers. | Gastroenterology | 2019 |
| 31040255 | Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy. | Oncologist | 2019 |
| 31011205 | Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. | Nat Med | 2019 |
| 30770496 | Correction: RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors. | Clin Cancer Res | 2019 |